Options360

BioNTech earnings 3/30 pre-market

Long
Options360 Updated   
NASDAQ:BNTX   BioNTech SE
BioNTech Q4 December 21' earnings are on 3/30 pre-market 6:45am. BioNTech Se ADR (BNTX) reported Q3 September 2021 earnings of $14.56 per share on revenue of $7.2 billion. The consensus earnings estimate was $11.79 per share on revenue of $5.8 billion. Revenue grew 9,003.0% on a year-over-year basis. I'm long now because a P/E = 3.7 for a leading MRNA biotechnology company heading into earnings is a rare opportunity. Plus, I waited until today from the technical entry I planned on Friday. Here's levels on the 1-day chart:

Q4 December 21' Consensus:
P/E = 3.7
EPS = $8.45
Revenue = $4.48B

52 week high = $464
52 week low = $93

SMA200 = $217
SMA100 =$206

breakout = $179
R3 = $169
R2 = $159
R1 = $150
pivot = $140
S1 = $130
S2 = $120
S3 = $111
breakdown = $101

Do your own due diligence, your risk is 100% your responsibility. This is for educational and entertainment purposes only. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Good luck and happy trading friends...

*3x lucky 7s of trading*

7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet

7 Common mistakes:
+5% portfolio trades, capital risk management
Beware of analyst's motives
Emotions & Opinions
FOMO : bad timing, the market is ruthless, be shrewd
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation

7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big, organized desk
Reading books, playing chess
Sorted watch-list

Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
TTC - trend channel
AlertiT - notification
tickerTracker - MFI Oscillator
www.tradingview.com/u/growerik/
Comment:
BNTX just broke it's 3 month resistance level

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.